Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · Real-Time Price · USD
9.37
-0.17 (-1.83%)
At close: Jun 5, 2025, 4:00 PM
9.34
-0.03 (-0.27%)
After-hours: Jun 5, 2025, 4:00 PM EDT
Cartesian Therapeutics Revenue
Cartesian Therapeutics had revenue of $1.10M in the quarter ending March 31, 2025, a decrease of -81.16%. This brings the company's revenue in the last twelve months to $34.17M, up 31.91% year-over-year. In the year 2024, Cartesian Therapeutics had annual revenue of $38.91M with 49.64% growth.
Revenue (ttm)
$34.17M
Revenue Growth
+31.91%
P/S Ratio
6.12
Revenue / Employee
$517,773
Employees
66
Market Cap
242.41M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 38.91M | 12.91M | 49.64% |
Dec 31, 2023 | 26.00M | -84.77M | -76.53% |
Dec 31, 2022 | 110.78M | 25.70M | 30.21% |
Dec 31, 2021 | 85.08M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRNAC News
- 2 days ago - Cartesian Therapeutics Announces New Employment Inducement Grants - GlobeNewsWire
- 6 days ago - Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis - GlobeNewsWire
- 4 weeks ago - Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Cartesian Therapeutics' Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial - GlobeNewsWire
- 2 months ago - Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 3 months ago - Cartesian Therapeutics Announces New Employment Inducement Grant - GlobeNewsWire
- 3 months ago - Cartesian Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis - GlobeNewsWire